Cook Medical   Report issue

For profit Phase 3
Founded: Bloomington IN United States (1963)
Status: No NME R&D (1963)

Organization Overview

First Clinical Trial
2008
NCT00847535
First Marketed Drug
2000
iopamidol (Isovue)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cook | COOK IMAGING | Cook MyoSite | Cook Myosite, Inc. | Cook Research Incorporated

Active Ingredients

Marketed Drugs (1)

iopamidol (Isovue) (2000)

Drugs in Phase 3 Trials (2)

autologous muscle derived stem cells (12 trials)

iltamiocel (1 trial)

Drugs in Other Trials (3)

acetylsalicylic acid (aspirin) (1 trial)

allogeneic blood cells (1 trial)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 2)

Deglutition Disorders (Phase 1)

Enuresis (Phase 3)

Fecal Incontinence (Phase 2)

Heart Diseases (Phase 2)

Heart Failure (Phase 2)

Ischemia (Phase 2)

Lower Urinary Tract Symptoms (Phase 2)

Myocardial Ischemia (Phase 2)

Urinary Incontinence (Phase 3)

Urinary Incontinence, Stress (Phase 3)

Urination Disorders (Phase 2)

Urological Manifestations (Phase 2)

Urologic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 5